Home
    Disclaimer
    ← Back to Flualprazolam
    Flualprazolam molecular structure

    Flualprazolam Stats & Data

    Depressant Research-chemical Benzodiazepine
    F-alp Flualp 2'-fluoro-alprazolam
    NPS DataHub
    MW326.76
    FormulaC17H12ClFN4
    CAS28910-91-0
    IUPAC8-chloro-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
    SMILESClc1ccc2c(c1)C(=NCc1nnc(C)n12)c1ccccc1F
    InChIKeyMPZVLJCMGPYWQQ-UHFFFAOYSA-N
    Benzodiazepines; 2020/3. Benzodiazepine; 2021/3. Benzodiazepine; 2022/3. Benzodiazepine
    Chemical Class Benzodiazepine
    Psychoactive Class Depressant

    Receptor Profile

    Receptor Actions

    Modulators
    GABA-A receptor positive allosteric modulator (benzodiazepine site)

    History & Culture

    Flualprazolam was first synthesized in 1976 as part of broader benzodiazepine research, representing the triazolo analog of fludiazepam and structurally related to alprazolam as its 2'-fluoro derivative. Despite its early synthesis, the compound was never developed for pharmaceutical use and remained largely unknown for over four decades. The substance emerged on the online research chemical market in 2017, joining a growing number of novel benzodiazepine analogs being sold as designer drugs. Swedish forensic authorities first definitively identified flualprazolam in circulation in 2018. According to some reports, the compound has been marketed or deceptively sold as a replacement for alprazolam, the widely prescribed pharmaceutical benzodiazepine, despite the two substances differing in substantive ways. Its appearance on the designer drug market subsequently prompted international regulatory attention, with the World Health Organization recommending it for scheduling in December 2019.

    Effect Profile

    Curated + 7 Reports
    Benzodiazepine 7.7

    Strong anxiolysis, euphoria, and cognitive impairment with moderate sedation

    Anxiolysis×3
    10
    Sedation / Relaxation×2
    6
    Motor / Cognitive Impairment×1
    8
    Euphoria / Mood Lift×1
    10
    Based on reports from:
    Erowid Experience Reports PsychonautWiki Flualprazolam

    Tolerance & Pharmacokinetics

    drugs.wiki

    Tolerance Decay

    Full tolerance 3d Half tolerance 37d Baseline ~60d

    Cross-Tolerances

    Alprazolam
    85% ●○○
    Diazepam
    85% ●○○
    Clonazepam
    85% ●○○
    Lorazepam
    85% ●○○
    Etizolam
    85% ●○○
    Bromazolam
    85% ●○○
    Clonazolam
    85% ●○○
    Flubromazolam
    85% ●○○

    Experience Report Analysis

    Erowid
    7 Reports
    2019–2022 Date Range
    6 With Age Data
    3 Effects Detected

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid

    Effects aggregated from 7 experience reports (7 Erowid)

    7 Reports
    3 Effects Detected
    2 Positive
    1 Adverse
    0 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Positive Effects 2

    Sedation 57.1% 70%
    Euphoria 42.9% 70%

    Adverse Effects 1

    Memory Suppression 57.1% 70%

    Real-World Dose Distribution

    62K Doses

    From 14 individual dose entries

    Oral (n=5)

    Median: 1.0mg 25th: 1.0mg 75th: 1.5mg 90th: 1.8mg
    mg/kg median: 0.018 mg/kg 75th: 0.024
    Read full reports on Erowid →

    Legal Status

    UN Convention on Psychotropic Substances 1971 (Schedule II) - added March 2020
    Country Status Notes
    Germany Anlage II BtMG Listed under Anlage II of the Betäubungsmittelgesetz (Narcotics Act) as of January 21, 2021. This schedule designates it as a marketable controlled narcotic requiring prescription authorization.
    Poland IV-P group Placed under the IV-P group of controlled psychotropic substances as of March 11, 2021. Ownership, possession, and sale are prohibited under Polish law.
    Turkey Controlled substance Classified as a controlled drug under national drug legislation. Possession, production, supply, and importation are all prohibited.
    United Kingdom Psychoactive Substances Act 2016 Controlled under the blanket ban of the Psychoactive Substances Act rather than scheduled under the Misuse of Drugs Act. Production, supply, and possession with intent to supply carry criminal penalties.
    United States Schedule I Designated as a Schedule I controlled substance effective January 23, 2023. Classified as having high potential for abuse with no currently accepted medical use in treatment.

    References

    Data Sources

    Cited References

    ← Back to Flualprazolam